GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms

被引：5
|
作者：
Gomez-Peralta, Fernando [1 ]
Abreu, Cristina [1 ]
Rizzo, Manfredi [2 ]
机构：
[1] Gen Hosp Segovia, Unit Endocrinol & Nutr, Segovia, Spain
[2] Univ Palermo, Sch Med, Promise Dept, Palermo, Italy
来源：
JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2023年 / 37卷 / 08期
关键词：
GLP-1 receptor agonists; SGLT2; inhibitors; Safety; Clinical practice; Research; GLOMERULAR-FILTRATION-RATE; SEMAGLUTIDE; OUTCOMES;
D O I：
10.1016/j.jdiacomp.2023.108553
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
    Munir, Kashif M.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 773 - 777
  • [32] The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis
    Guo, Man
    Gu, Junling
    Teng, Fangyuan
    Chen, Jiao
    Ma, Xiumei
    Chen, Qing
    Pu, Yueli
    Jiang, Zongzhe
    Long, Yang
    Xu, Yong
    ENDOCRINE, 2020, 67 (02) : 294 - 304
  • [33] GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura
    Baroni, Marco Giorgio
    DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 193 - 212
  • [34] Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
    Muller, Dion R. P.
    Stenvers, Dirk J.
    Malekzadeh, Arjan
    Holleman, Frederik
    Painter, Rebecca C.
    Siegelaar, Sarah E.
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [35] Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on risk of diabetic eye complications
    Tsai, Yi-Hsuan
    Hemphill, Nefertiti OjiNjideka
    Kurth, Tobias
    DIABETOLOGIA, 2025, 68 (01) : 247 - 248
  • [36] Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
    Lin, Donna Shu-Han
    Yu, An-Li
    Lo, Hao-Yun
    Lien, Cheng-Wei
    Lee, Jen-Kuang
    Chen, Wen-Jone
    DIABETOLOGIA, 2022, 65 (12) : 2032 - 2043
  • [37] Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
    Sawami, Kosuke
    Tanaka, Atsushi
    Node, Koichi
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [38] Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
    Wright, Alison K. K.
    Carr, Matthew J. J.
    Kontopantelis, Evangelos
    Leelarathna, Lalantha
    Thabit, Hood
    Emsley, Richard
    Buchan, Iain
    Mamas, Mamas A. A.
    van Staa, Tjeerd P. P.
    Sattar, Naveed
    Ashcroft, Darren M. M.
    Rutter, Martin K. K.
    DIABETES CARE, 2022, 45 (04) : 909 - 918
  • [39] SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
    Gurgle, Holly E.
    White, Karen
    McAdam-Marx, Carrie
    VASCULAR HEALTH AND RISK MANAGEMENT, 2016, 12 : 239 - 249
  • [40] Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus
    Kim, Chee Hae
    Hwang, In-Chang
    Choi, Hong-Mi
    Ahn, Chang Ho
    Yoon, Yeonyee E.
    Cho, Goo-Yeong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 364 : 104 - 111
12345